AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Avalyn Pharma Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$23.33−0.33 (-1.39%)
Close on Oct 19, 2026
- Market cap
- $691.75M
- P/E (TTM)
- –
- Dividend yield
- –
Avalyn Pharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Avalyn Pharma | Industry median |
|---|---|---|
| Market Cap | $1.03B | $166.30M |
| Enterprise Value | $696.67M | $88.19M |
| PB Ratio | 2.60 | 2.03 |
| P/TBV Ratio | 2.60 | 2.29 |
Balance sheet
| Measure | Avalyn Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $352.43M | $61.43M |
| Total Debt | $14.80M | $118.52M |
| Net Cash (Debt) | $337.62M | $15.35M |
| Net Cash Per Share | $7.62 | $0.66 |
| Equity (Book Value) | $398.35M | $49.09M |
| Book Value Per Share | $8.99 | $1.37 |
| Tangible Book Value | $398.35M | $23.52M |
| Working Capital | $347.18M | $76.81M |
Financial position
| Measure | Avalyn Pharma | Industry median |
|---|---|---|
| Current Ratio | 33.12 | 3.34 |
| Quick Ratio | 32.60 | 2.44 |
| Debt / Equity | 0.04 | 0.52 |
Shares
| Measure | Avalyn Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 44,333,100 | 58,127,000 |
| Shares Change (QoQ) | 3497.2% | 0.54% |
| Float | 31,215,700 | 49,136,700 |
| Shares Held by Insiders | 29.6% | 11.6% |
| Shares Held by Institutions | 99.3% | 59.4% |
Scores
| Measure | Avalyn Pharma | Industry median |
|---|---|---|
| Altman Z-Score | 22.82 | -0.22 |
Calculated by StockData from Avalyn Pharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.